Patent: 10,004,747
✉ Email this page to a colleague
Summary for Patent: 10,004,747
Title: | Combination therapy |
Abstract: | The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor. |
Inventor(s): | Klein; Thomas (Radolfzell, DE), Grempler; Rolf (Birkenhard/Warthausen, DE), Mark; Michael (Biberach an der Riss, DE) |
Assignee: | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) |
Application Number: | 15/428,594 |
Patent Claims: | see list of patent claims |
Details for Patent 10,004,747
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Glaxosmithkline Llc | TANZEUM | albiglutide | For Injection | 125431 | 04/15/2014 | ⤷ Try a Trial | 2030-05-05 |
Eli Lilly And Company | TRULICITY | dulaglutide | Injection | 125469 | 09/18/2014 | ⤷ Try a Trial | 2030-05-05 |
Eli Lilly And Company | TRULICITY | dulaglutide | Injection | 125469 | 09/04/2020 | ⤷ Try a Trial | 2030-05-05 |
Sanofi-aventis U.s. Llc | ADLYXIN | lixisenatide | Injection | 208471 | 07/27/2016 | ⤷ Try a Trial | 2030-05-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |